BioMarin Pharmaceuticalvs.Regeneron
BMRN vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 6.1× larger than BioMarin Pharmaceutical by market cap; Regeneron trades at the lower P/E (15.7 vs 42.6); year to date, BioMarin Pharmaceutical leads (−0.5% vs −13.9%).
Side by side
| BMRN | REGN | |
|---|---|---|
| Market cap | $11.4B | $69.7B |
| Price | $59.12 | $664.52 |
| Today | −1.4% | −0.5% |
| Return YTD | −0.5% | −13.9% |
| Return 1Y | +0.5% | +18.7% |
| P/E | 42.6 | 15.7 |
| P/S | 3.5 | 4.7 |
| P/B | 1.8 | 2.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BioMarin PharmaceuticalBMRN
Biopharma specialized in enzyme and gene therapies for rare genetic diseases.
Full BMRN profile →RegeneronREGN
American biotech company focused on antibody-based medicines in ophthalmology, immunology and oncology.
Full REGN profile →More comparisons in Biotech & innovation
See where BMRN and REGN sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →